IL6 and cancer: In advanced cancer patients with the overt cancer-cachexia syndrome, the immunological function is severely impaired, characterized by a deficit in cell-mediated immunity associated with chronic inflammation and high levels of proinflammatory cytokines (IL-1, IL-6, and TNF-α) and acute-phase inflammatory proteins [fibrinogen and C-reactive protein (CRP)].